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Summary  24 
 Background: Strangulating small intestinal disease (SSID) carries a poor prognosis for survival 25 
in comparison to other types of colic, particularly if resection is required. Identification of 26 
markers which aid early diagnosis may prevent the need for resection, assist with more accurate 27 
prognostication, and/or support the decision on whether surgical intervention is likely to be 28 
successful, would be of significant welfare benefit.   29 
 Objectives: To apply an unbiased methodology to investigate the plasma and peritoneal fluid 30 
(PF) proteomes in horses diagnosed with SSID requiring resection, to identify novel biomarkers 31 
which may be of diagnostic or prognostic value.   32 
 Study Design: Prospective clinical research study.  33 
 Methods: Plasma and PF from horses presented with acute abdominal signs consistent with 34 
SSID were collected at initial clinical examination. Samples from eight horses diagnosed with 35 
SSID at surgery in which resection of affected bowel was performed, and four control horses 36 
euthanased for orthopaedic conditions were submitted for liquid chromatography tandem mass 37 
spectrometry. Protein expression profiles were determined using label-free quantification. Data 38 
were analysed using analysis of variance to identify differentially expressed proteins between 39 
control and all SSID horses and SSID horses which survived to hospital discharge and those 40 
which did not. Significance was assumed at p<0.05   41 
 Results: A greater number of proteins were identified in PF than plasma of both SSID cases and 42 
controls, with 123 PF and 13 plasma proteins significantly differentially expressed (DE) between 43 
cases and controls (p<0.05, ≥2-fold-change).  Twelve PF proteins (p<0.036) and four plasma 44 
proteins (p<0.05) were significantly DE between SSID horses which survived and those which 45 
did not.  46 
 Main Limitations: Major limitations are the low number of samples analysed, variation in 47 
duration and severity of SSID and only short-term outcome was considered.   48 
 Conclusions: Changes in PF proteome may provide a sensitive indicator of small intestinal 49 
strangulation and provide biomarkers relevant to prognosis.  50 
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 51 
Introduction  52 
Colic due to small intestinal obstruction is associated with a significantly lower survival rate than 53 
caecal or large intestinal obstruction [1, 2]. Likelihood of survival is further decreased with 54 
strangulating rather than simple obstruction and if resection following ischaemic insult is required [3, 55 
4]. The greatest mortality occurs in the first 7-10 days post-operatively, frequently as a result of 56 
recurrent colic, post-operative ileus and cardiovascular instability consistent with endotoxaemia [5, 6, 57 
7]. There are also significant welfare and financial concerns associated with subjecting a horse to 58 
major abdominal surgery and these concerns are particularly relevant when the prospects for short 59 
term survival may be poor.  60 
Total protein (TP) concentration of plasma and peritoneal fluid (PF) is routinely measured during 61 
clinical investigation to determine the presence of dehydration and protein losing transudative or 62 
exudative enteropathies but is non-specific for primary aetiology. Low plasma TP [7, 8] and elevated 63 
PF protein concentration [3] have been associated with non-survival, but these are not consistent 64 
findings [4, 9]. Peritoneal fluid is an ultrafiltrate of plasma which is produced normally to facilitate 65 
separation between parietal and visceral peritoneal surfaces of abdominal viscera [10]. Sanguinous or 66 
serosanguinous appearance of PF has been associated with increased incidence of post-operative 67 
complications and reduced survival [9] but must be differentiated from iatrogenic contamination due 68 
to needle perforation of cutaneous or serosal vessels, or splenic penetration. Qualitative analysis of 69 
protein content of these fluids may provide more specific information on the disease process and 70 
severity than quantitative assessment. Mass spectrometry-based label-free quantitative proteomics 71 
offers a highly automated, reproducible and accurate means of analysing complex mixtures such as 72 
biological fluids. Direct comparison between different samples can be made, allowing investigation of 73 
relative protein composition and abundances, without the need for expensive, time-consuming and 74 
complex labelling techniques, making it well suited to clinical biomarker discovery which typically 75 
requires higher sample throughput [11].  76 
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The primary aim of this study was to compare the plasma and PF proteomes from control horses 77 
without gastrointestinal disease with horses requiring intestinal resection due to strangulating small 78 
intestinal disease (SSID), and between those horses which subsequently survived to hospital discharge 79 
and those which did not. We hypothesised that PF would be a more sensitive marker of SSID, 80 
producing more significant changes than those occurring in the plasma and that it may be possible to 81 
identify protein biomarkers associated with survival or non-survival. Additionally, we hypothesised 82 
that a proteomic approach would identify proteins associated with biochemical pathways triggered or 83 
disrupted as a consequence of SSID which may provide therapeutic targets to improve post-operative 84 
survival. 85 
Materials and Methods 86 
Sample collection 87 
Following institutional ethical committee approval VREC219/a, blood and peritoneal fluid were 88 
collected during initial clinical examination from horses presented to the University of Liverpool 89 
Philip Leverhulme Equine Hospital with colic signs consistent with SSID. Following clipping and 90 
aseptic preparation of the ventral abdomen immediately caudal to the xiphisternum, a 21gauge 2-inch 91 
needlea was introduced slowly through the abdominal wall, to penetrate the coelomic cavity. 92 
Peritoneal fluid was collected by free flow into sterile plain blood collection tubesb. If blood 93 
contamination or enterocentesis occurred, the needle was withdrawn, and a second needle introduced. 94 
These horses were then excluded from the study. Blood was collected from the jugular vein by direct 95 
percutaneous venepuncture and placed into lithium heparin tubesb. Samples were immediately 96 
centrifuged at 1500 rcf for four minutes to sediment cellular component, the supernatant was 97 
harvested and frozen in 1mL aliquots at -80oC. Samples submitted for subsequent analysis by liquid 98 
chromatography tandem mass spectrometry (LC-MS/MS) and label-free quantification were  from 3 99 
cohorts: 1) horses with SSID which underwent resection of small intestine and subsequently survived 100 
to be discharged from the hospital (survivors) (n=4); 2)  horses with SSID which underwent resection 101 
of small intestine, recovered from surgery but were subsequently euthanased as a consequence of the 102 
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disease process (non-survivors) (n=4); 3) horses of similar age, euthanased for chronic orthopaedic 103 
conditions with no history or signs of gastrointestinal or peritoneal disease (controls) (n=4). 104 
Demographic information, with clinical and outcome details of SSID horses included in the study are 105 
provided in Table 1. 106 
Sample preparation 107 
Five milligrams of plasma and PF from each horse was bound to 10 μL of ProteoMiner™ Beadsc to 108 
compress the dynamic range of proteins. Beads were washed with phosphate buffered saline prior to 109 
binding and mixed with plasma or PF for 2 hours at room temperature, then washed with 25 mM 110 
ammonium bicarbonate (AmBic). One hundred and fifty microliters of 25 mM AmBic and 10 μL of 111 
0.05% Rapigest™ d was added to the beads and shaken at 550 rpm for 10 min at 80°C. Samples were 112 
reduced by the addition of 10 μL of 60 mM dithioreitol and incubated at 60°C for 10 minutes, then 113 
alkylated by the addition of 10 μL of 180 mM iodoacetamide and incubated at room temperature for 114 
30 minutes in the dark.  Proteomic grade trypsine was reconstituted in 25 mM  acetic acid to  a 115 
concentration of  0.2 μg μL-1 and 10 μL added to the samples to achieve an enzyme:protein ratio 116 
approximately 1:50 w/w. Following overnight  incubation on  a  rotating  mixer at  37°C, digestion 117 
was terminated and Rapigest™ d removed by acidification with 1 μL trifluoroacetic acid and 118 
incubation at 37°C for 45 min, then centrifugation at 15,000 rcf for 30  min. To check for complete 119 
digestion each sample was analysed pre- and post-acidification by SDS-PAGE.   120 
 121 
LC-MS/MS 122 
For LC-MS/MS analysis, a 2 μL injection was analysed using an Ultimate 3000 RSLC™ nano 123 
systemf coupled to a QExactive™ mass spectrometerf. Samples were loaded onto the trapping column 124 
PepMap100, C18, 300 μm x 5 mmf using partial loop injection, for seven minutes at a flow rate of 4 125 
μL min-1 with 0.1% (v/v) FA. Samples were then resolved on the analytical column Easy-Spray C18 126 
75 μm x 500  mm 2 μm columnf, using a gradient of 97% A (0.1% formic acid), 3% B (99.9% ACN 127 
0.1%  formic acid), to 60% A, 40% B, over 90 minutes, at a flow rate of 300 nL min-1. A spray 128 
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voltage of 1.7 kV was used with a capillary temperature of 280°C. Technical replicates were not run 129 
and blanks were not used between runs due to the very low (typically < 0.01%) carry-over of the 130 
system. 131 
  132 
The data-dependent (DDA) program used for data acquisition consisted of a 70,000 resolution full-133 
scan MS scan (AGC set to 1e6 ions with a maximum fill time of 250 ms) with the 10 most abundant 134 
peaks selected for MS/MS using a 17,000 resolution scan (AGC set to 5e4 ions with a maximum fill 135 
time of 250 ms) with an ion selection window of 3 m/z and a normalised collision energy of 30. To 136 
avoid repeated selection of peptides for MS/MS the program used a 30 second dynamic exclusion 137 
window.   138 
Data analysis 139 
Label free relative quantification was performed with Progenesis QITM version 2d, with plasma and 140 
peritoneal fluid analyses handled independently. The Progenesis QI workflow creates a virtual 141 
aggregate run comprising all data from individual samples, allowing features to be cross identified 142 
from other samples. This overcomes the stochastic sampling limitations of DDA when the sample is 143 
too complex for the duty cycle of the mass spectrometer. Respective abundance values of all proteins 144 
identified in all samples are reported, rather than qualitative lists of protein identifications for each 145 
sample. Samples were aligned according to retention time using a combination of manual and 146 
automatic alignment. Default peak picking parameters were applied and features with charges from 147 
1+ to 4+ featuring three or more isotope peaks were retained. A Mascot Generic Fileg created by 148 
Progenesis QITM  was searched against the Uniprot reference proteome for horse (downloaded April 149 
2015, 22,963 entries).  A fixed carbamidomethyl modification for cysteine and variable oxidation 150 
modification for methionine were specified. A precursor mass tolerance of 10 ppm and a fragment ion 151 
mass tolerance of 0.01 Da were applied.  To maximise the number of proteins identified for 152 
subsequent quantification, protein identification threshold was set at >1 unique peptide. The results 153 
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were then filtered to obtain a peptide false discovery rate (FDR) of 1%.  The protein identification list 154 
was then re-imported into Progenesis QITM for analysis of differential expression. Analysis of variance 155 
(ANOVA) of the mean normalised abundance of each protein was performed across the experimental 156 
groups, using the groupings ‘Controls’, ‘All SSID horses’, ‘SSID survivors’ and ‘SSID non-157 
survivors’, with the level of significance set at p<0.05.Those proteins with a  ≥2.0 fold-change (FC) 158 
between comparator groups were reported. Due to the large number  (123) of PF proteins returned as 159 
significant between Controls and All SSID horses using the stringency criteria p<0.05, ≥2 fold 160 
change, >1 peptide, this result was further adjusted for FDR q<0.05. 161 
Results  162 
Protein identification 163 
A greater number of proteins were reported in PF than plasma in all cohorts, based on identification 164 
using >1 unique peptide. Numbers [mean±SD (range)] of plasma and PF proteins respectively were: 165 
control 274.5±5.9 (268-282) and 330.5±23.4 (303-350); survivors 298.5±22.5 (284 -332) and 166 
335.2±7.8 (325-343); and non-survivors 292.5±4.7 (286-296) and 549±501.2 (122-1268). These 167 
differences were not statistically significant between groups (p=0.08 for plasma; p=0.5 for PF). 168 
Details for individual horses are given in Table 1.   169 
Control versus all SSID horses 170 
Thirteen plasma proteins and 123 PF proteins were significantly differentially expressed (DE) 171 
between control and all SSID horses (p<0.05, ≥2 fold change, >1 peptide). The number of significant 172 
PF proteins reduced to 45 when adjusted for false discovery rate (q<0.05). Four of these proteins were 173 
also significantly DE in plasma. Table S1 (Supplementary Information) lists these proteins and their 174 
distribution between fluid types, with UniProt accessions and number of unique peptides used for 175 
identification.  176 
SSID survivors versus non-survivors 177 
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Four plasma proteins and 12 PF proteins were DE between SSID horses which survived to hospital 178 
discharge and those which did not (p<0.05). None of these proteins were common to both fluids. Two 179 
proteins in both plasma (monocyte differentiation antigen CD14 precursor peptide and plasminogen) 180 
and PF (basic transcription factor 3 and proteasome subunit alpha 3) showed increased expression 181 
associated with non-survival, with the remainder significantly reduced. All 12 PF proteins were also 182 
significantly DE between control and all SSID horses, with direction of change consistent between 183 
controls and SSID and survival and non-survival, suggesting a continuum of expression change. 184 
Magnitude and direction of change of these 16 proteins is given in Table 2. Identification details of 185 
these proteins are given in Table S1 and normalised relative abundances are given in Table 186 
S2 (Supplementary Information). 187 
Discussion 188 
The pathological changes occurring in SSID are complex and rapidly progressive, resulting from both 189 
obstruction to the gut lumen and partial or complete vascular occlusion. Small intestinal mucosa 190 
shows ultrastructural changes within minutes of ischaemic insult, becoming necrotic within 2-4 hours. 191 
Degenerative changes continue following restoration of perfusion and motility [12], complicating 192 
accurate prognostic assessment. Previous studies have attempted to identify pre-, intra- and post-193 
operative physiological, surgical and biochemical factors [4, 8, 9, 13] which can inform likelihood of 194 
post-operative survival. This is the first study to use an unbiased approach to describe changes in 195 
plasma and PF proteomes and we report distinct differences in both biofluids between horses 196 
suffering from SSID and controls, and between horses with SSID which survived to hospital 197 
discharge and those which did not. Of the 45 PF proteins DE between controls and all SSID horses, 198 
12 were also DE between survivors and non-survivors, suggesting a continuum of expression levels of 199 
these markers with increasing disease severity. Fewer plasma proteins were DE overall, and 200 
interestingly none of those associated with non-survival were significant at the control versus all SSID 201 
level, or common to significant PF proteins. The most clinically relevant outcome from this study is 202 
9 
 
identification of 16 proteins DE between the surviving and non-surviving cohorts and these proteins 203 
are discussed below. 204 
Plasma proteins 205 
Two of the four DE plasma proteins are associated with haemostatic balance. Beta tubulin 1 class VI 206 
is a cytoskeletal protein found only in platelets and mature megakaryocytes [14]. Upregulation in 207 
survivors indicates primary haemostatic activity in response to vascular degeneration. Plasmin is the 208 
predominant fibrinolytic enzyme found in the circulation and extracellular matrix and increased 209 
expression of its zymogen in non-survivors may reflect dysregulation of the pro-/anti-coagulation 210 
balance, predisposing to a more thrombogenic state.  211 
The two other significant plasma proteins are mainly associated with cell survival and inflammation. 212 
Heat shock proteins (HSP) are typically expressed in the cytosol, nucleus or organelles, with HSP 213 
family A member 5 restricted to the endoplasmic reticulumin [15]. These proteins mediate 214 
intracellular trafficking and processing of both constitutively expressed proteins involved in cellular 215 
homeostasis and stress induced proteins associated with cell survival, consistent with our finding of 216 
highest expression in survivors.  217 
Progressive loss of mucosal barrier function facilitates translocation of luminal Gram negative 218 
bacteria into the peritoneal cavity, from where they can be rapidly absorbed into the systemic 219 
circulation. Macrophage surface antigen CD14 acts in concert with the TLR4 receptor to co-ordinate 220 
and modulate the host immune response to bacterial lipopolysaccharide (LPS) [16].  Increased 221 
expression of its precursor peptide, demonstrated in our non-survival cohort, likely represents a 222 
response to increased systemic LPS challenge.  223 
Peritoneal fluid proteins 224 
A greater proportion of significant peritoneal fluid proteins were associated with inflammation. As a 225 
primary interface between the host and its external environment, the intestinal mucosa possesses both 226 
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innate and adaptive immune regulatory function, comprised of both discrete lymphoid aggregates and 227 
diffuse populations of leukocytes distributed throughout the mucosa [17]. 228 
The exopeptidase carboxypeptidase E (CPE) is produced by specialised entero-endocrine cells (EEC) 229 
and processes peptide hormones such substance P, somatostatin and vasoactive intestinal peptide to 230 
their active forms. Neuropeptides are expressed in the intestinal mucosa by EEC and peptidergic 231 
neurones closely associated with mucosal lymphoid tissue and mast cells and exhibit both pro- and 232 
anti-inflammatory effects, depending on specific peptide and sub-population of leukocyte [17]. The 233 
importance of CPE to maintenance of intestinal homeostasis has been demonstrated using cpe-/- mice, 234 
where loss of enzyme expression produced increased baseline mucosal levels of IL-6 and greater 235 
response to chemically induced colitis, an effect reversible by administration of recombinant enteric 236 
neuropeptides [18]. Reduced levels of CPE in the non-surviving cohort would suggest dysregulated 237 
cytokine expression in these animals, likely resulting in greater intestinal inflammation. 238 
Circulating levels of retinol binding protein 4 (RBP4) correlate highly with insulin resistance, 239 
metabolic syndrome and cardiovascular disease in humans [19]. Present in glandular and smooth 240 
muscle cells of the small intestine, RBP4 is the sole retinol transport molecule in the blood and 241 
demonstrates indirect inhibition of insulin signalling through induction of pro-inflammatory cytokines 242 
via the JNK and TLR4 pathways [19]. Activation of NADPH oxidase and NF-κB has also been 243 
demonstrated in human vascular endothelial cells, inducing production of pro-inflammatory 244 
molecules involved in leukocyte recruitment and adherence [20]. Reduced expression with SSID and 245 
particularly in non-survivors is therefore interesting and contrary to expectations. However, RBP4 246 
levels also correlate with dietary intake of retinol, whilst intense exercise and the acute phase protein 247 
TNFα both downregulate RBP4 expression [21]. Reduced expression may therefore reflect greater 248 
duration or severity of intestinal dysfunction and/or increased levels of pain-associated physical 249 
activity, whilst still being compatible with a systemic inflammatory response. 250 
Leucine rich repeat neuronal 4 (LRRN4) is a validated and highly expressed marker of primary 251 
mesothelial cells [22]. The mesothelial cell monolayer comprising the visceral and parietal 252 
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peritoneum is highly reactive, capable of recognising microbial pathogen surface antigens following 253 
loss of intestinal barrier function and serosal leakage. Free floating mesenchymal cells become 254 
recruited to areas of tissue damage and under these conditions, mesothelial-mesenchymal transition 255 
(MMT) can occur, cells assuming a more fibroblast-like phenotype [23]. This increases the likelihood 256 
of serosal fibrosis and adhesion formation, predisposing to persistent dysmotility and recurrence of 257 
colic signs, major causes of death in the early post-operative period [4, 7].  Lowest LRRN4 levels in 258 
non-survivors may indicate greater MMT in this cohort, secondary to more extensive disease.  259 
Effective mucosal barrier function relies on mechanical as well as immunological integrity [24]. 260 
Increased trans- and intra-mural tension from intraluminal fluid sequestration and intramural oedema 261 
and haemorrhage, compound the risk of disruption to tissue architecture already compromised by 262 
hypoxic necrosis of serosal mesothelium and mucosal epithelium. Several of our significant PF 263 
proteins exhibit important extracellular matrix (ECM) associated functions, often in conjunction with 264 
inflammatory or other properties. 265 
Serpin family A member 1 is a serine proteinase inhibitor which, whilst primarily regulating the 266 
proteolytic activity of neutrophil elastase, also has activity against plasmin, thrombin and 267 
plasminogen activator, as well as functioning as an acute-phase protein with anti-inflammatory and 268 
immunomodulatory properties [25, 26]. Reduced expression in non-survivors would likely increase 269 
proteolytic activity in the ECM and contribute to inflammation and changes in coagulation.  270 
Secretion of galectin 3 binding protein stimulates IL-6 expression in stromal cells [27] and its 271 
associated protein Galectin-3 is widely distributed in epithelial cells, dendritic cells, mast cells, 272 
neutrophils, monocytes/macrophages and lymphocytes, with reduced expression associated with 273 
reduced intracellular adhesion in human intestinal epithelial cells [28]. Gal3-/- mice exhibit obtunded 274 
peritoneal macrophage and lymphocyte infiltration and increased sensitivity of peritoneal 275 
macrophages to apoptotic stimuli [29]. Lowest expression in non-survivors may, therefore, indicate 276 
disruption to the inflammatory response as well as reduced mechanical integrity of the intestinal 277 
epithelial barrier.   278 
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A Disintegrin and Metalloprotease-like Decysin 1 (ADAMDEC1) possesses atypical metalloprotease 279 
activity, functioning independently of normal intrinsic inhibitory mechanisms regulating 280 
metalloproteases [30]. Interestingly, and consistent with our findings, higher expression appears to be 281 
protective.  Down regulation is associated with Crohn’s disease in human patients [31] and a role in 282 
intestinal immunity and inflammation has been shown using Adamdec1-/- mice.  When exposed to 283 
oral Citrobacter or Salmonella challenge, knock-out mice demonstrated increased susceptibility to 284 
colitis, weight loss and mortality, associated with increased translocation of bacteria to the systemic 285 
circulation [31].  286 
Peptidase inhibitor 16 (PI16) is an extracellular protease and potent inhibitor of MMP-2 highly 287 
expressed by endothelial cells subjected to normal and elevated shear stress. Profound downregulation 288 
by low or oscillatory flow states and pro-inflammatory cytokines increases susceptibility to 289 
proteolytic sub-endothelial matrix degradation and endothelial detachment [32]. Reduced expression 290 
would, therefore, be expected in isolated tissues with compromised perfusion and from circulating 291 
inflammatory cytokines and a disturbed systemic circulation, conditions consistent with SSID. Lower 292 
PI16 expression identified in non-survivors is compatible with greater compromise to vascular and 293 
intestinal wall integrity in these individuals. 294 
The enzyme β-1, 4-glucuronyltransferase 1 initiates the process of glycosylation of the α-subunit of 295 
the transmembrane protein dystroglycan, acting as a priming enzyme for other glycosyltransferases to 296 
complete the complex post-translational modifications necessary to produce the functional molecule 297 
[33]. Dystroglycan is a ubiquitously expressed cell adhesion molecule with crucial roles in basement 298 
membrane assembly [34]. Extensively studied due to its role in muscular dystrophies, dystroglycan 299 
has also been shown to play an important role in the regulation of interactions between intestinal 300 
epithelial cells and the extracellular matrix [35]. Reduced expression associated with poor outcome 301 
may indicate a reduced ability to maintain intestinal epithelial barrier function. 302 
Amine oxidase enzymes catalyse the oxidative deamination of primary amines, with the production of 303 
ammonia and hydrogen peroxide. Primary amine oxidase is found in serum, smooth muscle, adipose 304 
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tissue and endothelium of mammals [36], whilst diamine oxidase is expressed in high concentrations 305 
in the intestinal mucosa [37]. Plasma diamine oxidase levels increase during gut development, 306 
becoming static at maturity, and have been shown to alter reciprocally with experimentally induced 307 
small intestinal mucosal damage in the adult rat [37], compatible with lowest expression in our non-308 
surviving SSID cohort. 309 
Tenascins are ECM glycoproteins generally exhibiting limited expression in healthy adult tissues, but 310 
early upregulation at sites of injury and inflammation. Tenascins contain a fibrinogen-like globe 311 
(FBG) domain, conserved between all family members which has been shown to drive inflammation 312 
by TLR4 receptor activation, inducing NF-κB and IL-6, IL-8 and TNF synthesis [38]. Interestingly, 313 
tenascin-X shows an almost opposite pattern of activity and expression to other family members, 314 
being more highly constitutively expressed, particularly in connective tissue and the muscularis 315 
mucosae of the digestive tract, where it functions to regulate cell-matrix interactions and expression 316 
and assembly of fibrillar collagens and elastic fibres.  Tenascin-X induces little or no NF-κB and 317 
cytokine activation, with weak or absent expression in early tissue injury, only becoming upregulated 318 
during resolution of injury, coincident with extracellular matrix assembly and maturation [38, 39]. 319 
Lowest expression in non-survivors is, therefore, consistent with ongoing inflammation and failure to 320 
resolve intestinal wall degradation. 321 
The two PF proteins highest in the non-survivor cohort were basic transcription factor 3 like 4 (BTF3) 322 
and proteasome subunit alpha, type 3 (PSMA3). The general RNA polymerase II BTF3 is involved in 323 
cell cycle regulation and apoptosis, with increased expression demonstrated in a range of human 324 
carcinomas, promoting transcription and protein synthesis and reducing apoptotic activity [40].  325 
PSMA3 forms the key substrate recognition element of the cells core protein degradation unit the 20S 326 
proteasome. Normally constitutively synthesised, increased and modified production is induced by 327 
TNF-α, IFN-γ or lipopolysaccharides [41]. Principally intracellular constituents, increases in both 328 
these proteins may indicate increases in both the anabolic and catabolic functions of cellular 329 
metabolism, or reflect leakage of intracellular content from ischaemic tissue. 330 
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Several limitations to this study must be recognised. Although ages and sexes were similar between 331 
survivors, non-survivors and controls, this represents a clinical cohort and it was, therefore, not 332 
possible to match these exactly. Typically for discovery proteomics, a relatively small number of 333 
samples was investigated, generating a comprehensive identification of proteins, but at the expense of 334 
sensitivity. A targeted approach, based on the proteins of interest identified would allow a greater 335 
sample throughput, increasing sensitivity, and this work is currently ongoing, as is validation of our 336 
findings in both dependent and independent cohorts. There is also the opportunity to extend this work 337 
to other types of colic for comparison. Although our findings suggest a continuum of expression 338 
levels of some PF proteins between controls, survivors and non-survivors, inclusion of horses with 339 
non-strangulating small intestinal disease would be a useful addition to further explore the clinical 340 
utility of developing our approach. Biological fluids are complex mixtures and highly abundant 341 
proteins can obscure changes in those expressed at lower concentrations.  We utilised ProteominerTM 342 
beads in the initial stages of sample processing to address this complication. This technology 343 
selectively reduces the concentration of highly abundant proteins by their combination with peptide 344 
ligands anchored in a solid phase, reducing the dynamic range of protein concentrations in the sample, 345 
obtunding this masking effect. It is, however, possible that some residual effect remained. To 346 
maximise throughput of biological replicates, we did not run technical replicates or blanks between 347 
samples. We have previously identified minimal technical variation and sample carry-over with our 348 
workflow, but future work should incorporate these elements. 349 
In conclusion, we have demonstrated a greater abundance of DE proteins in PF than plasma in 350 
response to SSID and between survivors and non-survivors. The proteins we have identified 351 
associated with non-survival to hospital discharge principally coordinate immunomodulation, cell 352 
adhesion and matrix integrity, haemostatic balance and cell cycle regulation, indicating the range of 353 
pathophysiological sequelae of SSID. Further analysis of these proteins and their associated pathways 354 
may identify potential targets for post-operative therapeutic intervention to aid in securing a 355 
successful outcome. Validating the utility of these proteins as biomarkers of prognosis also offers the 356 
potential to develop a stable-side test which may aid in clinical decision making. 357 
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Table 1. Details of control horses and pathology, surgical procedure and outcome of eight horses 479 
with strangulating small intestinal disease. 480 
 481 
 Number  of proteins 
(concentration) 
PF gross 
appearance 
Pathology/surgical 
procedure 
Outcome 
Horse Plasma PF 
8yr old Dales gelding 284 
(68g/L) 
325 
(40g/L) 
Haemorrhagic EFE; 6m resection; 
jejunoileostomy 
Survived to discharge (32 
days) 
17yr old cob gelding 289 
(69g/L) 
334 
(8g/L) 
Clear, pale 
yellow 
PL; 2.75m resection; 
jejunojejunostomy 
Survived to discharge (9 
days) 
13yr old Clydesdale  
gelding 
289 
(68g/L) 
339 
(26g/L) 
Serosanguinous PL; 0.75m resection; 
jejunojejunostomy  
Survived to discharge (9 
days) 
14yr old Welsh Cob 
mare 
332 
(62g/L) 
343 
(22g/L) 
Clear yellow PL; 1.5m resection; 
jejunojejunostomy 
Survived to discharge (10 
days) 
6yr old Warmblood 
gelding 
292 
(62g/L) 
122 
(36g/L) 
Sanguinous MR; 3.5m resection; 
jejunojejunostomy 
Euthanased 5 days later due 
to POR 
10yr old Irish Sport 
Horse mare 
296 
(65g/L) 
1268* 
(58g/L) 
Haemorrhagic EFE; 6.75m resection; 
jejunojejunostomy 
Euthanased 12 days later due 
to chronic intra-abdominal 
haemorrhage/shock 
19yr old 
Thoroughbred cross 
gelding 
296 
(68g/L) 
327 
(32g/L)  
Serosanguinous Cause of strangulation not 
identified at surgery; 6.5m 
resection; jejunoileostomy 
Euthanased 4 days later due 
to POR 
17yr old Welsh Cob 
mare 
286 
(65g/L) 
479 
(42g/L)  
Serosanguinous PL; 3m resection; 
jejunojejunostomy 
Euthanased 8 days later at 
relaparotomy; multiple 
adhesions 
12yr old Cob gelding 272 
(68g/L) 
350 
(4g/L) 
Clear, pale 
yellow 
Control  
18yr old Irish Draft 
cross gelding 
268 
(59g/L) 
350 
(2g/L) 
Clear, 
colourless 
Control  
17yr old Irish Draft 
mare 
282 
(66g/L) 
303 
(1g/L) 
Clear,  
colourless  
Control  
9yr old Irish Draft 
cross gelding 
276 
(66g/L) 
319 
(2g/L) 
Clear, pale 
yellow 
Control  
PF peritoneal fluid; EFE epiploic foramen entrapment; PL pedunculated lipoma; MR mesenteric rent; POR post-operative 
reflux;* haemolysed sample. 
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Table 2. Plasma and peritoneal fluid proteins significantly differentially expressed (>2 fold 482 
change in normalised abundance) for SSID survival versus non-survival analysis. Data also 483 
given for control versus SSID cases for peritoneal fluid proteins as the same proteins were 484 
significantly differentially expressed in both cohorts.   485 
Protein Control versus SSID Survival versus non-survival 
 
Max 
fold 
change 
ANOVA 
(p) 
Highest 
mean 
condition 
Max 
fold 
change 
ANOVA 
(p) 
Highest 
mean 
condition 
Peritoneal Fluid       
Carboxypeptidase E -8.8 0.001 Control -5.8 0.007 Survival 
Retinol binding protein 4  -3.2 0.017 Control -4.9 0.007 Survival 
Peptidase inhibitor 16  -3.0 0.032 Control -4.8 0.012 Survival 
Tenascin-X -3.1 0.007 Control -2.8 0.016 Survival 
ADAM-like decysin 1 -4.1 0.006 Control -4.2 0.020 Survival 
Serpin family A member 1 -3.2 0.001 Control -2.2 0.020 Survival 
Amine oxidase  -3.5 0.017 Control -3.1 0.024 Survival 
Beta-1,4-
glucuronyltransferase 1 
-2.9 0.003 Control -2.5 0.026 Survival 
Leucine rich repeat neuronal 
4 
-5.5 0.005 Control -4.1 0.028 Survival 
Galectin 3 binding protein  -7.6 0.0004 Control -4.1 0.029 Survival 
Basic transcription factor 3 
like 4 
23.8 0.030 SSID 16.3 0.035 Non-
Survival 
Proteasome  subunit alpha, 
type 3 
21.1 0.032 SSID 13.4 0.036 Non-
Survival 
       
Plasma       
Heat shock protein family A 
(Hsp70) member 5  
   -2.3 0.03 Survival 
Tubulin beta 1 class VI    -3.9 0.05 Survival 
Monocyte differentiation 
antigen CD14 precursor 
peptide 
   3.2 0.05 Non-
survival 
Plasminogen    
 2.1 0.05 Non-
survival 
SSID – Strangulating Small Intestinal Disease.  
 486 
